





The ubiquitin system, a larger drug target opportunity than kinases?

Targeting kinase enzymes has grown to dominate drug discovery over the last decade, accounting for 30% of current pharma R&D. The analogous ubiquitin cell signalling system is the next big opportunity beyond kinases representing greater therapeutic reach. Ubiquigent has the access to the necessary technology, skills and experience to deliver integrated Drug Discovery Programmes to support our partners to exploit this rapidly developing field.



The ubiquitin system, a larger drug target opportunity than kinases?

A typical DUB drug discovery integrated programme is given below by way of example; a similar but modified approach could be applied to other ubiquitin system targets.



Ubiquigent's scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems.

The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.

Ubiquigent benefits from high calibre backing including from private US investors, the UK Medical Research Council, and the University of Dundee. The company's headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen).

In addition to Ubiquigent's own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.

Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry, that enables the company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.



For further information please contact:

Ubiquigent Ltd
Sir James Black Centre, Dow Street, Dundee, Scotland, DD1 5EH, UK

Tel: +44 (0) 1382 388292
partnerships@ubiquigent.com

www.ubiquigent.com

1.0

